Compare PLSE & ATRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | ATRC |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2015 | 2005 |
| Metric | PLSE | ATRC |
|---|---|---|
| Price | $25.30 | $28.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $22.00 | ★ $51.17 |
| AVG Volume (30 Days) | 326.9K | ★ 830.1K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.74 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $201,630,000.00 |
| Revenue This Year | $840.00 | $15.27 |
| Revenue Next Year | $287.54 | $12.21 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.40 |
| 52 Week Low | $12.56 | $25.52 |
| 52 Week High | $27.98 | $43.18 |
| Indicator | PLSE | ATRC |
|---|---|---|
| Relative Strength Index (RSI) | 61.28 | 50.92 |
| Support Level | $17.58 | $26.47 |
| Resistance Level | $26.30 | $30.75 |
| Average True Range (ATR) | 1.72 | 1.46 |
| MACD | 0.59 | 0.10 |
| Stochastic Oscillator | 74.53 | 69.26 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.